Dog /

Breed profile · FDA CVM July 2026 extract

Mastiff (unspecified) adverse-event record

Adverse-event filings for Mastiff (unspecified) (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.

#134 of 510
by report volume (all breeds)
569
FDA CVM reports on file
9.8%
death-coded share of reports
#50 of 275
by death-coded share (≥50 reports)

How the 569 reports break down

By recorded gender -- every report on file for Mastiff (unspecified), no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 253 189.75 126.5 63.25 0 2017 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Mastiff (unspecified) drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Mastiff (unspecified) ranks #134 of 510 by total reports (569) and #50 of 275 by death-coded share (9.8%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#134
This breed, reports of 510
#50
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Mastiff (unspecified) has 569 reports now versus 522 in that prior snapshot: 47 more (9.0%).

Report change
+47
Death-coded reports
+3
Death-coded share
−0.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Mastiff (unspecified) changes

Total Reports

569

Above-median volume

Deaths Reported

56

of 569 reports

Death-coded share of reports

9.8%

High death-coded share

Avg Age at Report

5.3 yr

52.5 kg avg weight

Breed Safety Scorecard

F (6/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate F
9.8%

Share of reports coded as a fatality

Euthanasia rate F
6.3%

Share of reports resulting in euthanasia

Full recovery rate F
14.1%

Share of reports coded "Recovered/Normal"

5-year trend F
+23200%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Mastiff (unspecified) death-coded reports 9.8%
Cross-breed median

9.8% of 569 mastiff (unspecified) reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Mastiff (unspecified)'s death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

10% 82nd percentile Higher share than 82% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). This entry sits in this band. 20%–25%: 2 indexed breeds (1%). Above this entry. 25%–30%: 3 indexed breeds (1%). Above this entry. 30%–35%: 4 indexed breeds (1%). Above this entry. 35%–40%: 5 indexed breeds (2%). Above this entry. 40%–45%: 6 indexed breeds (2%). Above this entry. 45%–50%: 3 indexed breeds (1%). Above this entry. 50%–55%: 7 indexed breeds (3%). Above this entry. 55%–60%: 7 indexed breeds (3%). Above this entry. 60%–65%: 21 indexed breeds (8%). Above this entry. 65%–70%: 11 indexed breeds (4%). Above this entry. 70%–75%: 15 indexed breeds (5%). Above this entry. 75%–80%: 13 indexed breeds (5%). Above this entry. 80%–85%: 11 indexed breeds (4%). Above this entry. 85%–90%: 12 indexed breeds (4%). Above this entry. 90%–95%: 12 indexed breeds (4%). Above this entry. 95%–100%: 142 indexed breeds (52%). Above this entry. Mastiff (unspecified) 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Average weight at time of report: 52.5 kg (115.8 lbs)

Top Reported Reactions

Lack of efficacy (endoparasite) - heartworm 64
Vomiting 58
Lethargy (see also Central nervous system depression in Neurological) 57
Lack of efficacy - NOS 40
Lack of efficacy (bacteria) - Borrelia 40
Death by euthanasia 36
Seizure NOS 33
Diarrhoea 32

Most Referenced Drugs

Pyrantel Pamoate;Sarolaner 139
Bedinvetmab 137
Moxidectin 48
Carprofen 43
Fluralaner 13.64% 12-Week Chew 42
Oclacitinib Maleate 35
Gabapentin 34
Ivermectin + Pyrantel As Pamoate Salt 32

Outcome Breakdown

Ongoing
290 (50.9%)
Outcome Unknown
144 (25.3%)
Recovered/Normal
80 (14.0%)
Euthanized
36 (6.3%)
Died
20 (3.5%)

Gender Distribution

Male 340 (59.8%)
Female 213 (37.4%)
Unknown 15 (2.6%)
Mixed 1 (0.2%)

Reports by Year

Year Reports Trend
2014 2
2017 1
2020 2
2021 1
2022 5
2023 36
2024 253
2025 233
2026 36

Mastiff (unspecified): high death-coded share in the FDA CVM extract

Signature read: Mastiff (unspecified)'s 9.8% death-coded share is in the upper third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Mastiff (unspecified) sits at #134 of 510 by report volume among all breeds and #111 of 298 among dog breeds, with 569 reports and 56 (9.8%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #50 of 275. Mean age at report: 5.3 years, average weight 52.5 kg (115.8 lbs).

Top reported signs: Lack of efficacy (endoparasite) - heartworm (64), Vomiting (58), Lethargy (see also Central nervous system depression in Neurological) (57). Most-referenced drug: Pyrantel Pamoate;Sarolaner (139 reports), followed by Bedinvetmab (137) and Moxidectin (48).

Outcome coding on 570 status-recorded reports is dominated by Ongoing (50.9%). Annual submissions ranged 1-2,026 across 9 years on file.

Dog Breeds With a Similar Report Volume

Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.

Nationwide breeds with similar profiles

High-volume peer sets for Mastiff (unspecified) drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar death-coded share

Nearest other-species breeds with ≥50 reports (9.8% death-coded here).

Similar average weight

Nearest other-species breeds by reported average weight (52.5 kg here).

What to do with this dog

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Mastiff (unspecified)?
There are 569 adverse event reports involving Mastiff (unspecified) in the FDA database, of which 56 were death-coded (9.8% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Mastiff (unspecified) ranks #134 of 510 by report volume among all breeds PlainBreed indexes (#111 of 298 among dog breeds).
Where does Mastiff (unspecified) sit among other breeds in PlainBreed's corpus?
According to FDA CVM report volume, Mastiff (unspecified) is #134 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #111 of 298. Among breeds with at least 50 reports, its death-coded share ranks #50 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Mastiff (unspecified)?
The most commonly reported adverse reactions for Mastiff (unspecified) are Lack of efficacy (endoparasite) - heartworm (64 reports), Vomiting (58 reports), Lethargy (see also Central nervous system depression in Neurological) (57 reports), Lack of efficacy - NOS (40 reports), Lack of efficacy (bacteria) - Borrelia (40 reports).
What drugs are most frequently associated with Mastiff (unspecified) adverse events?
The drugs most frequently referenced in Mastiff (unspecified) adverse event reports are Pyrantel Pamoate;Sarolaner (139 reports), Bedinvetmab (137 reports), Moxidectin (48 reports), Carprofen (43 reports), Fluralaner 13.64% 12-Week Chew (42 reports).
What is the average age of Mastiff (unspecified) in adverse event reports?
The average age of Mastiff (unspecified) at the time of adverse event reports is 5.3 years, with an average weight of 52.5 kg (115.8 lbs).

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Mastiff (unspecified) (Dog), extract as of July 2026 extract. 569 reports · 56 death-coded (9.8% of reports, not a mortality rate) · #134 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →